This updated article clarifies the nature of Karl Voelkerding's new relationship with EraGen. The researcher was appointed, not hired, by the company.
NEW YORK, Aug. 7 - EraGen Biosciences on Tuesday said it had appointed clinical pathologist Karl Voelkerding to serve on its scientific board.
Voelkerding, who is president of Gene Insight and president of the assocation for molecular pathology, will help EraGen, based in Madison, Wis., as it speeds up its efforts to commercialize its nucleic acid and bioinformatics technologies, the company said.
"EraGen has developed novel nucleic acid and informatics tools and technologies that are facilitating the integration of genomics into pharmaceutical discovery and basic research," Voelkerding said in a statement released Monday.
"As a member of the scientific board, I will be focusing my efforts on the strategic expansion of EraGen into diagnostic product development," he said.
Voelkerding, who will not retain a salary as a member of EraGen's scientific board, said his first aim would be to help the company deliver its genotyping and gene quantitation systems to clinical labs.
EraGen licenses bioinformatics tools, drug screening platforms, and nucleic acid and genotyping technologies for clinical diagnostic and life science research applications.
Earlier this month, the company announced that it had won a grant worth roughly $750,000 from the National Institutes of Health to develop its Master Catalog functional genomics software platform.